Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pollen-related allergic rhinoconjunctivitis treatment strategies in children
NL-OMON41233Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of fluticasone propionate and levocetirizine in allergic rhinoconjunctivitis (ARC), allergic rhinitis (AR) and asthma (3 arms), sponsored by Erasmus MC. Primary endpoints: Percentage of symptom-free days and Asthma Control Test score. Started Mar 2013; status: active, not recruiting.
02
Drugs
fluticasone propionatelevocetirizine
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on NL-OMON41233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41233.